Valuation: AstraZeneca PLC

Market Cap 264B 229B 213B 196B 370B 25,177B 376B 2,515B 987B 12,534B 990B 969B 42,028B P/E 2026 *
21.8x
P/E 2027 * 19x
Enterprise Value 284B 247B 230B 211B 398B 27,091B 404B 2,707B 1,062B 13,487B 1,066B 1,042B 45,224B EV / Sales 2026 *
4.48x
EV / Sales 2027 * 4.13x
Free-Float
96.63%
Yield 2026 *
1.96%
Yield 2027 * 2.07%
1 day-0.34%
1 week-1.36%
1 month-13.48%
3 months-6.11%
6 months-5.16%
Current year-4.46%
1 week 1,616
Extreme 1616
1,699
1 month 1,587
Extreme 1587
1,872
Current year 1,587
Extreme 1587
1,925.5
1 year 1,365
Extreme 1365
1,925.5
3 years 1,226
Extreme 1226
1,925.5
5 years 960.3
Extreme 960.3
1,925.5
10 years 461.3
Extreme 461.3
1,925.5
Manager TitleAgeSince
Chief Executive Officer 66 01/10/2012
Director of Finance/CFO 52 01/08/2021
Compliance Officer - 01/01/2023
Director TitleAgeSince
Director/Board Member 70 06/04/1999
Director/Board Member 66 01/10/2012
Director/Board Member 65 27/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
-0.34%-1.36% - - 264B
-0.53%-3.95%+50.70%+152.78% 1,024B
+0.21%-2.68%+53.20%+50.87% 618B
-2.51%-3.25%+28.54%+67.99% 443B
+0.06%-0.42%+37.53%+31.06% 349B
-7.37%-4.40%-0.74%-43.66% 209B
-0.64%+2.43%+29.74%+67.16% 208B
-0.82%+0.70%+15.05%+72.05% 162B
+0.40%+1.92%+6.47%-29.25% 143B
+0.69%+5.19%+47.66%+5.77% 133B
Average -1.09%-0.60%+29.79%+41.64% 365.4B
Weighted average by Cap. -0.91%-1.86%+38.40%+73.60%

Financials

2026 *2027 *
Net sales 63.28B 55.01B 51.2B 47.01B 88.78B 6,041B 90.15B 604B 237B 3,007B 238B 232B 10,084B 66.85B 58.12B 54.09B 49.66B 93.79B 6,382B 95.24B 638B 250B 3,177B 251B 246B 10,654B
Net income 12.09B 10.51B 9.78B 8.98B 16.95B 1,154B 17.22B 115B 45.24B 574B 45.39B 44.39B 1,926B 13.71B 11.92B 11.09B 10.19B 19.23B 1,309B 19.53B 131B 51.32B 652B 51.49B 50.36B 2,185B
Net Debt 20.05B 17.43B 16.23B 14.9B 28.13B 1,914B 28.57B 191B 75.07B 953B 75.31B 73.66B 3,196B 12.56B 10.92B 10.16B 9.33B 17.62B 1,199B 17.9B 120B 47.02B 597B 47.18B 46.14B 2,002B
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
31/07/26 SEK 1,627.50 -0.34% 417,185
30/07/26 SEK 1,633.00 -3.57% 756,672
29/07/26 SEK 1,693.50 +1.35% 595,230
28/07/26 SEK 1,671.00 -0.33% 593,299
27/07/26 SEK 1,676.50 +1.61% 634,985
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
170.04USD
Average target price
212.34USD
Spread / Average Target
+24.87%

Quarterly revenue - Rate of surprise